Fig. 1 | British Journal of Cancer

Fig. 1

From: A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

Fig. 1

Phase-II Kaplan-Meier curves of (A) time to tumour progression by central independent review assessed according to Response Evaluation Criteria for Solid Tumours (RECIST) v1.0, (B) overall survival, and (C) progression-free survival by central independent review assessed according to RECIST v1.0. OS, overall survival; PFS, progression-free survival; TTP, time to progression

Back to article page